Quest Clinical Research   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: San Francisco CA United States (1997)
Status: Acquired by eStudySite (2015)

Organization Overview

First Clinical Trial
2002
NCT00033176
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Quest Clinical Research | Quest Clinical Research, San Francisco | Quest Clinical Research, San Francisco, California

Active Ingredients

Drugs in Phase 4 Trials (4)

bictegravir (Biktarvy) (1 trial)

doravirine (pifeltro) (1 trial)

emtricitabine (emtriva) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

Drugs in Phase 2 Trials (2)

alpha-lipoic acid (1 trial)

yk-fh312 (1 trial)

Drugs in Phase 1 Trials (2)

mva (1 trial)

scy-635 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

HIV Infections (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Smallpox (Phase 1)

Vaccinia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8